D-brane scattering and annihilation

We study the dynamics of parallel brane-brane and brane-antibrane scattering in string theory in flat spacetime, focusing on the pair production of open strings that stretch between the branes. We are particularly interested in the case of scattering at small impact parameter $b < l_s$, where there is a tachyon in the spectrum when a brane and an antibrane approach within a string length. Our conclusion is that despite the tachyon, branes and antibranes can pass through each other with only a very small probability of annihilating, so long as $g_s$ is small and the relative velocity $v$ is neither too small nor too close to 1. Our analysis is relevant also to the case of charged open string production in world-volume electric fields, and we make use of this T-dual scenario in our analysis. We briefly discuss the application of our results to a stringy model of inflation involving moving branes.Comment: 25+7 pages, 5 figure

Unwinding Inflation

Higher-form flux that extends in all 3+1 dimensions of spacetime is a source of positive vacuum energy that can drive meta-stable eternal inflation. If the flux also threads compact extra dimensions, the spontaneous nucleation of a bubble of brane charged under the flux can trigger a classical cascade that steadily unwinds many units of flux, gradually decreasing the vacuum energy while inflating the bubble, until the cascade ends in the self-annihilation of the brane into radiation. With an initial number of flux quanta Q_{0} \simgeq N, this can result in N efolds of inflationary expansion while producing a scale-invariant spectrum of adiabatic density perturbations with amplitude and tilt consistent with observation. The power spectrum has an oscillatory component that does not decay away during inflation, relatively large tensor power, and interesting non-Gaussianities. Unwinding inflation fits naturally into the string landscape, and our preliminary conclusion is that consistency with observation can be attained without fine-tuning the string parameters. The initial conditions necessary for the unwinding phase are produced automatically by bubble formation, so long as the critical radius of the bubble is smaller than at least one of the compact dimensions threaded by flux.Comment: 29+15 pages, 10 figures, published versio

Inflation from Flux Cascades

When electric-type flux threads compact extra dimensions, a quantum nucleation event can break a flux line and initiate a cascade that unwinds many units of flux. Here, we present a novel mechanism for inflation based on this phenomenon. From the 4D point of view, the cascade begins with the formation of a bubble containing an open Friedmann-Robertson-Walker cosmology, but the vacuum energy inside the bubble is initially only slightly reduced, and subsequently decreases gradually throughout the cascade. If the initial flux number Q_0 ~ O(100), during the cascade the universe can undergo N ~ 60 efolds of inflationary expansion with gradually decreasing Hubble constant, producing a nearly scale-invariant spectrum of adiabatic density perturbations with amplitude and tilt consistent with observation, and a potentially observable level of non-Gaussianity and tensor modes. The power spectrum has a small oscillatory component that does not decay away during inflation, with a period set approximately by the light-crossing time of the compact dimension(s). Since the ingredients are fluxes threading compact dimensions, this mechanism fits naturally into the string landscape, but does not appear to suffer from the eta problem or require fine-tuning (beyond the usual anthropic requirement of small vacuum energy after reheating).Comment: 5 pages, 1 figur

Large-scale anomalies from primordial dissipation

We analyze an inflationary model in which part of the power in density perturbations arises due to particle production. The amount of particle production is modulated by an auxiliary field. Given an initial gradient for the auxiliary field, this model produces a hemispherical power asymmetry and a suppression of power at low multipoles similar to those observed by WMAP and Planck in the CMB temperature. It also predicts an additive contribution to $\delta T$ with support only at very small $l$ that is aligned with the direction of the power asymmetry and has a definite sign, as well as small oscillations in the power spectrum at all $l$.Comment: 1+15 pages, 7 figure

Extra virgin olive oil and cardiovascular diseases: benefits for human health

The cardioprotective properties of Mediterranean Diet were demonstrated for the first time from the Seven Country Study. In the last few decades, numerous epidemiological studies, as well as intervention trial, confirmed this observation, pointing out the close relationship between the Mediterranean diet and cardiovascular diseases. In this context, extra virgin olive oil (EVOO), the most representative component of this diet, seems to be relevant in lowering the incidence of cardiovascular events, including myocardial infarction and stroke. From a chemical point of view, 98-99% of the total weight of EVOO is represented by fatty acids, especially monounsaturated fatty acids such as oleic acid. Tocopherols, polyphenols and other minor constituents represent the remaining 1-2%. All these components may potentially contribute to "health maintenance" with their beneficial effects by EVOOO

Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors

In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti-factor VIII antibodies, known as 'inhibitors'. Drugs insensitive to such antibodies, either recombinant or plasma-derived, are called factor VIII 'by-passing' agents and used for treatment of bleeding in people with inhibitors

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis

Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biologics. Although there is consensus that these therapies reduce the frequency of relapses, their relative benefit in delaying new relapses or disability worsening remains unclear due to the limited number of direct comparison trials

rates of latent tuberculosis infection using different diagnostica test

Background.The interferon−g−release assays (IGRA) are emerging as an attractive alternative to the tuberculin skin test (TST) for the diagnosis of latent tuberculosis infection (LTBI).The absence of a gold standard for LTBI hampers the assessment of any diagnostic test. Methods.In a prospective study,229 patients (mean age 35.5±24.6 y) from different ward of the Hospital (Respiratory Diseases,Dermatology, Rheumatology, Pediatrics, Infectious Diseases, Hematology and Transplant Unit) were simultaneously tested for a suspect of either LTBI or active tuberculosis using all commercially available diagnostics: TST,QuantiFERON−TB Gold (QFT−2G), QuantiFERON−TB Gold In−Tube(QFT−3G) and T−SPOT.TB(TS.TB). Results. 42(18.3%),37(16.2%),59(25.8%) and 79(34.5%) patients were positive with TST,QFT−2G,QFT−3G and TS.TB, respectively.TS.TB(p<0.001) and QFT−3G(p=0.016) provided more positive results than TST, while no difference was found for TST and QFT−2G(p=0.53).All IGRA showed a good overall agreement (TS.TB vs QFT−2G,k=0.55; TS.TB vs QFT−3G,k=0.72;QFT−2G vs QFT−3G, k=0.62). In 22 subjects (9.6%) QFT−3G was positive and QFT−2G negative. Indeterminate results were more frequent with QFT−2G(18.3%) and QFT−3G (12.7%) than with TS.TB(1.3%,p<0.0001). Conclusion. Rates of LTBI as detected by different diagnostic tests may have significant variations. Performances of various IGRA formats were variable in this population

Prenatal education for congenital toxoplasmosis

Congenital toxoplasmosis is considered a rare but potentially severe infection. Prenatal education about congenital toxoplasmosis could be the most efficient and least harmful intervention, yet its effectiveness is uncertain

Major discrepancies between what clinical trial registries record and paediatric randomised controlled trials publish

Background: Whether information from clinical trial registries (CTRs) and published randomised controlled trial (RCTs) differs remains unknown. Knowing more about discrepancies should alert those who rely on RCTs for medical decision-making to possible dissemination or reporting bias. To provide help in critically appraising research relevant for clinical practice we sought possible discrepancies between what CTRs record and paediatric RCTs actually publish. For this purpose, after identifying six reporting domains including funding, design, and outcomes, we collected data from 20 consecutive RCTs published in a widely read peer-reviewed paediatric journal and cross-checked reported features with those in the corresponding CTRs. Methods: We collected data for 20 unselected, consecutive paediatric RCTs published in a widely read peer-reviewed journal from July to November 2013. To assess discrepancies, two reviewers identified and scored six reporting domains: funding and conflict of interests; sample size, inclusion and exclusion criteria or crossover; primary and secondary outcomes, early study completion, and main outcome reporting. After applying the Critical Appraisal Skills Programme (CASP) checklist, five reviewer pairs cross-checked CTRs and matching RCTs, then mapped and coded the reporting domains and scored combined discrepancy as low, medium and high. Results: The 20 RCTs were registered in five different CTRs. Even though the 20 RCTs fulfilled the CASP general criteria for assessing internal validity, 19 clinical trials had medium or high combined discrepancy scores for what the 20 RCTs reported and the matched five CTRs stated. All 20 RCTs selectively reported or failed to report main outcomes, 9 had discrepancies in declaring sponsorship, 8 discrepancies in the sample size, 9 failed to respect inclusion or exclusion criteria, 11 downgraded or modified primary outcome or upgraded secondary outcomes, and 13 completed early without justification. The CTRs for seven trials failed to index automatically the URL address or the RCT reference, and for 12 recorded RCT details, but the authors failed to report the results. Conclusions: Major discrepancies between what CTRs record and paediatric RCTs publish raise concern about what clinical trials conclude. Our findings should make clinicians, who rely on RCT results for medical decision-making, aware of dissemination or reporting bias. Trialists need to bring CTR data and reported protocols into line with published data